CD274 and neoplasm: Porter and colleagues combined the ability of oncolytic viruses, the immunostimulatory potential of cytokine IL-12, and the immune checkpoint blocker anti-PD-L1 with a BiTE specific for the tumor-specific antigen CD44 variant 6 [119].